The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Open accessAbstract
Ovarian cancer is the second most common cause of gynecologic cancer death in women around the world. The outcomes are complicated, because the disease is often diagnosed late and composed of several subtypes with distinct biological and molecular properties (even within the same histological subtype), and there is inconsistency in availability of and access to treatment. Upfront treatment largely relies on debulking surgery to no residual disease and platinum‐based chemotherapy, with the addition of antiangiogenic agents in patients who have suboptimally debulked and stage IV disease. Major improvement in maintenance therapy has been seen by incorporating inhibitors against poly (ADP‐ribose) polymerase (PARP) molecules involved in the DNA damage‐repair process, which have been approved in a recurrent setting and recently in a first‐line setting among women with BRCA1 / BRCA2 mutations. In recognizing the challenges facing the treatment of ovarian cancer, current investigations are enlaced with deep molecular and cellular profiling. To improve survival in this aggressive disease, access to appropriate evidence‐based care is requisite. In concert, realizing individualized precision medicine will require prioritizing clinical trials of innovative treatments and refining predictive biomarkers that will enable selection of patients who would benefit from chemotherapy, targeted agents, or immunotherapy. Together, a coordinated and structured approach will accelerate significant clinical and academic advancements in ovarian cancer and meaningfully change the paradigm of care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Ovarian cancer statistics, 2018
Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., Gaudet, M. M., Jemal, A., & Siegel, R. L. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21456 · Cited by 3,492
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Self-citationMcGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I., Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,537
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451
Self-citationIncorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Self-citationOzols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., & Wiltshaw, E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1748 · Cited by 1,866
Pujade-Lauraine, E., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,855
Self-citationColeman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J. I., Clamp, A., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,693
Self-citationOlaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,671
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
du Bois, A., Reuss, A., Pujade‐Lauraine, E., Harter, P., Ray‐Coquard, I., & Pfisterer, J. (2009) · Cancer · doi:10.1002/cncr.24149 · Cited by 1,638
Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,622
Canadian Cancer Statistics 2012: (611042012-001)
(2012) · PsycEXTRA Dataset · doi:10.1037/e611042012-001 · Cited by 1,492
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
van Driel, W. J., Koole, S. N., Sikorska, K., Schagen van Leeuwen, J. H., Schreuder, H. W. R., Hermans, R. H. M., de Hingh, I. H. J. T., van der Velden, J., Arts, H. J., Massuger, L. F. A. G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1708618 · Cited by 1,426
Kehoe, S., Hook, J., Nankivell, M., Jayson, G. C., Kitchener, H., Lopes, T., Luesley, D., Perren, T., Bannoo, S., Mascarenhas, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62223-6 · Cited by 1,414
Aghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D., Böhm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., et al. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4019 · Cited by 1,367
Staging classification for cancer of the ovary, fallopian tube, and peritoneum
Prat, J. (2014) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2013.10.001 · Cited by 1,364
Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196
Self-citationAlsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,180
Personalized vaccines for cancer immunotherapy
Sahin, U., & Türeci, Ö. (2018) · Science · doi:10.1126/science.aar7112 · Cited by 1,147
Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117
Self-citationColeman, M., Forman, D., Bryant, H., Butler, J., Rachet, B., Maringe, C., Nur, U., Tracey, E., Coory, M., Hatcher, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62231-3 · Cited by 1,114
Markman, M., Bundy, B. N., Alberts, D. S., Fowler, J. M., Clark-Pearson, D. L., Carson, L. F., Wadler, S., & Sickel, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1001 · Cited by 1,080
Pennington, K. P., Walsh, T., Harrell, M. I., Lee, M. K., Pennil, C. C., Rendi, M. H., Thornton, A., Norquist, B. M., Casadei, S., Nord, A. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2287 · Cited by 1,051
Jacobs, I. J., Menon, U., Ryan, A., Gentry-Maharaj, A., Burnell, M., Kalsi, J. K., Amso, N. N., Apostolidou, S., Benjamin, E., Cruickshank, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01224-6 · Cited by 1,048
Moore, R. G., McMeekin, D. S., Brown, A. K., DiSilvestro, P., Miller, M. C., Allard, W. J., Gajewski, W., Kurman, R., Bast, R. C., & Skates, S. J. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.08.031 · Cited by 875
Oza, A. M., Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00086-8 · Cited by 875
Self-citationHigh grade serous ovarian carcinomas originate in the fallopian tube
Labidi-Galy, S. I., Papp, E., Hallberg, D., Niknafs, N., Adleff, V., Noe, M., Bhattacharya, R., Novak, M., Jones, S., Phallen, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00962-1 · Cited by 759
Katsumata, N., Yasuda, M., Takahashi, F., Isonishi, S., Jobo, T., Aoki, D., Tsuda, H., Sugiyama, T., Kodama, S., Kimura, E., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61157-0 · Cited by 727
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj465 · Cited by 680
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
Daly, M. B., Pilarski, R., Berry, M., Buys, S. S., Farmer, M., Friedman, S., Garber, J. E., Kauff, N. D., Khan, S., Klein, C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0003 · Cited by 650
Identification of tissue-specific cell death using methylation patterns of circulating DNA
Lehmann-Werman, R., Neiman, D., Zemmour, H., Moss, J., Magenheim, J., Vaknin-Dembinsky, A., Rubertsson, S., Nellgård, B., Blennow, K., Zetterberg, H., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519286113 · Cited by 610
Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Walker, J. L., Kim, B.-G., Fujiwara, K., Tewari, K. S., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30279-6 · Cited by 609
Prat, J. (2012) · Virchows Archiv · doi:10.1007/s00428-012-1203-5 · Cited by 602
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma
Verhaak, R. G. W., Tamayo, P., Yang, J.-Y., Hubbard, D., Zhang, H., Creighton, C. J., Fereday, S., Lawrence, M., Carter, S. L., Mermel, C. H., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65833 · Cited by 569
Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage
Peres, L. C., Cushing-Haugen, K. L., Köbel, M., Harris, H. R., Berchuck, A., Rossing, M. A., Schildkraut, J. M., & Doherty, J. A. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy071 · Cited by 554
Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71135-0 · Cited by 547
Self-citationKim, G., Ison, G., McKee, A. E., Zhang, H., Tang, S., Gwise, T., Sridhara, R., Lee, E., Tzou, A., Philip, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0887 · Cited by 528
Walsh, T., Lee, M. K., Casadei, S., Thornton, A. M., Stray, S. M., Pennil, C., Nord, A. S., Mandell, J. B., Swisher, E. M., & King, M.-C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007983107 · Cited by 487
Konstantinopoulos, P. A., Spentzos, D., Karlan, B. Y., Taniguchi, T., Fountzilas, E., Francoeur, N., Levine, D. A., & Cannistra, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5719 · Cited by 483
Katsumata, N., Yasuda, M., Isonishi, S., Takahashi, F., Michimae, H., Kimura, E., Aoki, D., Jobo, T., Kodama, S., Terauchi, F., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70363-2 · Cited by 480
Kovtun, Y. V., Audette, C. A., Ye, Y., Xie, H., Ruberti, M. F., Phinney, S. J., Leece, B. A., Chittenden, T., Blättler, W. A., & Goldmacher, V. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3973 · Cited by 479
Folate receptor alpha as a tumor target in epithelial ovarian cancer
Kalli, K. R., Oberg, A. L., Keeney, G. L., Christianson, T. J. H., Low, P. S., Knutson, K. L., & Hartmann, L. C. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.11.020 · Cited by 475
Tan, D. S. P., Rothermundt, C., Thomas, K., Bancroft, E., Eeles, R., Shanley, S., Ardern-Jones, A., Norman, A., Kaye, S. B., & Gore, M. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1703 · Cited by 469
Copy number signatures and mutational processes in ovarian carcinoma
Macintyre, G., Goranova, T. E., De Silva, D., Ennis, D., Piskorz, A. M., Eldridge, M., Sie, D., Lewsley, L.-A., Hanif, A., Wilson, C., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0179-8 · Cited by 449
Farley, J., Brady, W. E., Vathipadiekal, V., Lankes, H. A., Coleman, R., Morgan, M. A., Mannel, R., Yamada, S. D., Mutch, D., Rodgers, W. H., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70572-7 · Cited by 413
Prat, J. (2015) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2015.26.2.87 · Cited by 411
Kondrashova, O., Nguyen, M., Shield-Artin, K., Tinker, A. V., Teng, N. N. H., Harrell, M. I., Kuiper, M. J., Ho, G.-Y., Barker, H., Jasin, M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0419 · Cited by 407
Self-citationPrognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer
Konecny, G. E., Wang, C., Hamidi, H., Winterhoff, B., Kalli, K. R., Dering, J., Ginther, C., Chen, H.-W., Dowdy, S., Cliby, W., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju249 · Cited by 398
Pignata, S., Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., Bologna, A., Weber, B., Raspagliesi, F., Panici, P. B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70049-x · Cited by 389
Momparler, R. L., & Bovenzi, V. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200005)183:2<145::aid-jcp1>3.0.co;2-v · Cited by 387
Immunotherapy in ovarian cancer
Odunsi, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx444 · Cited by 384
Jodrell, D. I., Egorin, M. J., Canetta, R. M., Langenberg, P., Goldbloom, E. P., Burroughs, J. N., Goodlow, J. L., Tan, S., & Wiltshaw, E. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.520 · Cited by 381
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
Jaaback, K., Johnson, N., & Lawrie, T. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005340.pub4 · Cited by 359
Banerjee, S., & Kaye, S. B. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2243 · Cited by 357
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Scott, C. L., Swisher, E. M., & Kaufmann, S. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8848 · Cited by 355
Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer
Zhang, A. W., McPherson, A., Milne, K., Kroeger, D. R., Hamilton, P. T., Miranda, A., Funnell, T., Little, N., de Souza, C. P. E., Laan, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.073 · Cited by 353
Percac-Lima, S., Grant, R. W., Green, A. R., Ashburner, J. M., Gamba, G., Oo, S., Richter, J. M., & Atlas, S. J. (2009) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0864-x · Cited by 344
Origin and molecular pathogenesis of ovarian high-grade serous carcinoma
Kurman, R. J. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt463 · Cited by 336
Yamaguchi, K., Mandai, M., Toyokuni, S., Hamanishi, J., Higuchi, T., Takakura, K., & Fujii, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1614 · Cited by 324
New insights into ovarian cancer pathology
Prat, J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds300 · Cited by 317
Pathogenesis and heterogeneity of ovarian cancer
Kroeger, P. T., & Drapkin, R. (2017) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000340 · Cited by 314
Antibody–Drug Conjugates for Cancer Treatment
Lambert, J. M., & Berkenblit, A. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-061516-121357 · Cited by 314
Wu, R., Hendrix-Lucas, N., Kuick, R., Zhai, Y., Schwartz, D. R., Akyol, A., Hanash, S., Misek, D. E., Katabuchi, H., Williams, B. O., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.016 · Cited by 313
Lancaster, J. M., Powell, C. B., Chen, L.-M., & Richardson, D. L. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.09.009 · Cited by 298
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease
Wilson, M. K., Pujade-Lauraine, E., Aoki, D., Mirza, M. R., Lorusso, D., Oza, A. M., du Bois, A., Vergote, I., Reuss, A., Bacon, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw663 · Cited by 289
Self-citationOvarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles
McConechy, M. K., Ding, J., Senz, J., Yang, W., Melnyk, N., Tone, A. A., Prentice, L. M., Wiegand, K. C., McAlpine, J. N., Shah, S. P., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.107 · Cited by 288
Omura, G., Blessing, J. A., Ehrlich, C. E., Miller, A., Yordan, E., Creasman, W. T., & Homesley, H. D. (1986) · Cancer · doi:10.1002/1097-0142(19860501)57:9<1725::aid-cncr2820570903>3.0.co;2-j · Cited by 278
Einzig, A. I., Wiernik, P. H., Sasloff, J., Runowicz, C. D., & Goldberg, G. L. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.11.1748 · Cited by 263
Global Health Equity: Cancer Care Outcome Disparities in High-, Middle-, and Low-Income Countries
de Souza, J. A., Hunt, B., Asirwa, F. C., Adebamowo, C., & Lopes, G. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.2860 · Cited by 225
Low‐grade serous carcinomas of the ovary contain very few point mutations
Jones, S., Wang, T., Kurman, R. J., Nakayama, K., Velculescu, V. E., Vogelstein, B., Kinzler, K. W., Papadopoulos, N., & Shih, I. (2012) · The Journal of Pathology · doi:10.1002/path.3967 · Cited by 218
Rosenthal, A. N., Fraser, L. S. M., Philpott, S., Manchanda, R., Burnell, M., Badman, P., Hadwin, R., Rizzuto, I., Benjamin, E., Singh, N., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.9330 · Cited by 209
Eliminating racial disparities in colorectal cancer in the real world: It took a village
Grubbs, S. S., Polite, B. N., Carney, J., Bowser, W., Rogers, J., Katurakes, N., Hess, P., & Paskett, E. D. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.8412 · Cited by 201
Risk Prediction for Late-Stage Ovarian Cancer by Meta-analysis of 1525 Patient Samples
Riester, M., Wei, W., Waldron, L., Culhane, A. C., Trippa, L., Oliva, E., Kim, S.-H., Michor, F., Huttenhower, C., Parmigiani, G., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju048 · Cited by 195
Global ovarian cancer health disparities
Chornokur, G., Amankwah, E. K., Schildkraut, J. M., & Phelan, C. M. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.12.016 · Cited by 190
Wiltshaw, E., & Kröner, P. T. (1976) · PubMed · Cited by 178
Widschwendter, M., Zikan, M., Wahl, B., Lempiäinen, H., Paprotka, T., Evans, I., Jones, A., Ghazali, S., Reisel, D., Eichner, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0500-7 · Cited by 172
Anti-angiogenic agents in ovarian cancer: past, present, and future
Monk, B. J., Minion, L. E., & Coleman, R. L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw093 · Cited by 171
Balasubramaniam, S., Beaver, J. A., Horton, S., Fernandes, L. L., Tang, S., Horne, H. N., Liu, J., Liu, C., Schrieber, S. J., Yu, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1337 · Cited by 167
Raich, P. C., Whitley, E. M., Thorland, W., Valverde, P., & Fairclough, D. L. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-0513 · Cited by 154
Karam, A., Ledermann, J. A., Kim, J.-W., Sehouli, J., Lu, K., Gourley, C., Katsumata, N., Burger, R. A., Nam, B.-H., Bacon, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx011 · Cited by 153
Skates, S. J., Greene, M. H., Buys, S. S., Mai, P. L., Brown, P. H., Piedmonte, M., Rodriguez, G. C., Schorge, J. O., Sherman, M. E., Daly, M. B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2750 · Cited by 145
Konstantinopoulos, P. A., Waggoner, S. E., Vidal, G. A., Mita, M. M., Fleming, G. F., Holloway, R. W., Le, L. V., Sachdev, J. C., Chapman‐Davis, E., Colón‐Otero, G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.106 · Cited by 143
Friedlander, M. L., Gebski, V., Gibbs, E., Davies, L. C., Bloomfield, R., Hilpert, F., Wenzel, L. B., Eek, D., Rodrigues, M. J., Clamp, A. R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30343-7 · Cited by 135
Characterization of Active Mitogen-Activated Protein Kinase in Ovarian Serous Carcinomas
Hsu, C., Bristow, R. E., Cha, M. S., Wang, B. G., Ho, C., Kurman, R. J., Wang, T., & Shih, I. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0893 · Cited by 132
Oza, A. M., Matulonis, U. A., Malander, S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30333-4 · Cited by 126
Self-citationGynecologic Cancer InterGroup (GCIG) Consensus Review for Mucinous Ovarian Carcinoma
Ledermann, J. A., Luvero, D., Shafer, A., O’Connor, D., Mangili, G., Friedlander, M. L., Pfisterer, J., Mirza, M. R., Kim, J., Alexandre, J., et al. (2014) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000296 · Cited by 118
Self-citationHowitt, B. E., Strickland, K. C., Sholl, L. M., Rodig, S. J., Ritterhouse, L. L., Chowdhury, D., D’Andrea, A. D., Matulonis, U. A., & Konstantinopoulos, P. A. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1277308 · Cited by 116
Shibuya, Y., Tokunaga, H., Saito, S., Shimokawa, K., Katsuoka, F., Li, B., Kojima, K., Nagasaki, M., Yamamoto, M. P., Yaegashi, N., et al. (2017) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22507 · Cited by 113
Itamochi, H., Oishi, T., Oumi, N., Takeuchi, S., Yoshihara, K., Mikami, M., Yaegashi, N., Terao, Y., Takehara, K., Ushijima, K., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.228 · Cited by 110
Etemadmoghadam, D., George, J., Cowin, P. A., Cullinane, C. M., Kansara, M., Chenevix‐Trench, G., Gorringe, K. L., Smyth, G. K., & Bowtell, D. D. L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015498 · Cited by 106
Lim, M. C., Chang, S., Yoo, H. J., Nam, B., Bristow, R. E., & Park, S. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5520 · Cited by 104
A Review of Mirvetuximab Soravtansine in the Treatment of Platinum-Resistant Ovarian Cancer
Moore, K. N., Martin, L. P., O’Malley, D. M., Matulonis, U. A., Konner, J. A., Vergote, I. B., Ponte, J. F., & Birrer, M. J. (2017) · Future Oncology · doi:10.2217/fon-2017-0379 · Cited by 104
Paskett, E. D., Katz, M. L., Post, D. M., Pennell, M. L., Young, G. S., Seiber, E. E., Harrop, J. P., DeGraffinreid, C. R., Tatum, C. M., Dean, J. A., et al. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-0523 · Cited by 101
Front-line therapy of advanced epithelial ovarian cancer: standard treatment
Marth, C., Reimer, D., & Zeimet, A. G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx450 · Cited by 94
Lheureux, S., Bruce, J. P., Burnier, J. V., Karakasis, K., Shaw, P. A., Clarke, B. A., Yang, S. Y. C., Quevedo, R., Li, T., Dowar, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3677 · Cited by 92
Self-citationWang, C., Armasu, S. M., Kalli, K. R., Maurer, M. J., Heinzen, E. P., Keeney, G. L., Cliby, W. A., Oberg, A. L., Kaufmann, S. H., & Goode, E. L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0246 · Cited by 91
PTEN expression in clear cell adenocarcinoma of the ovary
Hashiguchi, Y., Tsuda, H., Inoue, T., Berkowitz, R. S., & Mok, S. C. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.09.047 · Cited by 86
Long, B. J., Chang, J. J., Ziogas, A., Tewari, K. S., Anton‐Culver, H., & Bristow, R. E. (2014) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2014.10.1104 · Cited by 85
Gómez-Hidalgo, N. R., Martínez-Cannon, B. A., Nick, A. M., Lu, K. H., Sood, A. K., Coleman, R. L., & Ramirez, P. T. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.03.049 · Cited by 85
Disparity in Cancer Care: A Canadian Perspective
Ahmed, S., & Shahid, R. K. (2012) · Current Oncology · doi:10.3747/co.19.1177 · Cited by 83
Moore, K. N., Vergote, I. B., Oaknin, A., Colombo, N., Banerjee, S. N., Oza, A. M., Pautier, P., Malek, K. S., & Birrer, M. J. (2018) · Future Oncology · doi:10.2217/fon-2017-0646 · Cited by 79
Self-citationPignata, S., Lorusso, D., Joly, F., Gallo, C., Colombo, N., Sessa, C., Bamias, A., Pisano, C., Selle, F., Zaccarelli, E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.5506 · Cited by 74
Perineal Talc Use and Ovarian Cancer
Penninkilampi, R., & Eslick, G. D. (2017) · Epidemiology · doi:10.1097/ede.0000000000000745 · Cited by 73
The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment
Hilliard, T. S. (2018) · Cancers · doi:10.3390/cancers10090277 · Cited by 73
Oza, A. M., Selle, F., Давиденко, І., Korach, J., Mendiola, C., Pautier, P., Chmielowska, E., Bamias, A., DeCensi, A., Zvirbule, Z., et al. (2016) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000836 · Cited by 71
Self-citationMerritt, M. A., Rice, M. S., Barnard, M. E., Hankinson, S. E., Matulonis, U. A., Poole, E. M., & Tworoger, S. S. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30373-5 · Cited by 69
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors
McGee, J., Bookman, M. A., Harter, P., Marth, C., McNeish, I. A., Moore, K. N., Poveda, A. M., Hilpert, F., Hasegawa, K., Bacon, M. A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx010 · Cited by 65
Provencher, D. M., Gallagher, C., Parulekar, W. R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx754 · Cited by 65
Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium
Trabert, B. L., Poole, E. M., White, E., Visvanathan, K., Adami, H., Anderson, G. L., Brasky, T. M., Brinton, L. A., Fortner, R. T., Gaudet, M. M., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy100 · Cited by 63
Coleman, R. L., Enserro, D. M., Spirtos, N. M., Herzog, T. J., Sabbatini, P. J., Armstrong, D. K., Kim, B. S., Fujiwara, K., Walker, J. L., Flynn, P. J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.5501 · Cited by 58
Uehara, Y., Oda, K., Ikeda, Y., Koso, T., Tsuji, S., Yamamoto, S., Asada, K., Sone, K., Kurikawa, R., Makii, C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128066 · Cited by 57
Monk, B. J., & Chan, J. K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx451 · Cited by 53
Clamp, A. R., McNeish, I. A., Dean, A. P., Gallardo, D., Weon-Kim, J., O’Donnell, D. M., Hook, J., Coyle, C., Blagden, S. P., Brenton, J. D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440.039 · Cited by 51
HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?
Fotopoulou, C., Sehouli, J., Mahner, S., Harter, P., Nieuwenhuysen, E. V., González-Martı́n, A., Vergote, I. B., Chiva, L. M., & du Bois, A. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy198 · Cited by 45
Ovarian cancer treatment: The end of empiricism?
Lheureux, S., Karakasis, K., Kohn, E. C., & Oza, A. M. (2015) · Cancer · doi:10.1002/cncr.29481 · Cited by 41
Self-citationLee, Y. C., Jivraj, N., O'Brien, C. A., Chawla, T. P., Shlomovitz, E., Buchanan, S., Lau, J., Croke, J. M., Allard, J. P., Dhar, P., et al. (2018) · Obstetrics and Gynecology International · doi:10.1155/2018/1867238 · Cited by 41
Self-citationBurger, R. A., Enserro, D. M., Tewari, K. S., Brady, M. F., Bookman, M. A., Fleming, G. F., Huang, H. Q., Homesley, H. D., Fowler, J. M., Boente, M. P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.5517 · Cited by 37
Jang, J. Y. A., Yanaihara, N., Pujade-Lauraine, É., Mikami, Y., Oda, K., Bookman, M. A., Ledermann, J. A., Shimada, M., Kiyokawa, T., Kim, B., et al. (2017) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2017.28.e54 · Cited by 25
A mouse model for endometrioid ovarian cancer arising from the distal oviduct
van der Horst, P. H., van der Zee, M., Heijmans‐Antonissen, C., Jia, Y., DeMayo, F. J., Lydon, J. P., van Deurzen, C. H. M., Ewing, P. C., Burger, C. W., & Blok, L. J. (2014) · International Journal of Cancer · doi:10.1002/ijc.28746 · Cited by 24
How to approach patients in relapse
Pujade-Lauraine, É. (2012) · Annals of Oncology · doi:10.1093/annonc/mds358 · Cited by 23
Broekman, K. E., Jalving, M., van Tinteren, H., Sessa, C., & Reyners, A. K. L. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.06.008 · Cited by 13
Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer
Fujiwara, K., McAlpine, J. N., Lheureux, S., Matsumura, N., & Oza, A. M. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_158675 · Cited by 12
Self-citation
Cited by
CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy
Rosenblum, D., Gutkin, A., Kedmi, R., Ramishetti, S., Veiga, N., Jacobi, A. M., Schubert, M. S., Friedmann-Morvinski, D., Cohen, Z. R., Behlke, M. A., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc9450 · Cited by 614
CA125 and Ovarian Cancer: A Comprehensive Review
Charkhchi, P., Cybulski, C., Gronwald, J., Wong, F. O., Narod, S. A., & Akbari, M. R. (2020) · Cancers · doi:10.3390/cancers12123730 · Cited by 602
Fluorescent Probes for Disease Diagnosis
Wang, X., Ding, Q., Groleau, R. R., Wu, L., Mao, Y., Che, F., Kotova, O., Scanlan, E. M., Lewis, S. E., Li, P., et al. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00776 · Cited by 543
Woodhouse, R., Li, M., Hughes, J., Delfosse, D., Skoletsky, J., Ma, P., Meng, W., Dewal, N., Milbury, C., Clark, T., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0237802 · Cited by 516
Chen, B., Yu, P., Chan, W. N., Xie, F., Zhang, Y., Liang, L., Leung, K. T., Lo, K. W., Yu, J., Tse, G. M. K., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01679-y · Cited by 420
Metadata
- Authors
- Lheureux, S., Braunstein, M., & Oza, A. M.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2019-05-17
- Volume
- 69
- Issue
- 4
- Pages
- 280-304
- ISSN
- 0007-9235 (ISSN-L)
- 1542-4863
- OpenAlex
- W2945357020
- Cited by
- 1,423
- References
- 143
- FWCI
- 119.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.